Prof. Gisbert Schneider meets Dr. Matthias Zentgraf from Boehringer Ingelheim Pharma to discuss challenges for RETHINK.
The RETHINK initiative of ETH Zurich brings together experts from industry and academia to exploit the potential of artificial intelligence for design processes. ETH Prof. Gisbert Schneider and Dr. Matthias Zentgraf (Boehringer Ingelheim Pharma) explain the benefits for drug design and plan the future collaborative tasks.
For further information about the ETH Industry day visit the homepage of ETH.
